List of Excipients in Branded Drug SODIUM PHENYLACETATE AND SODIUM BENZOATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium phenylacetate and sodium benzoate	68682-001	HYDROCHLORIC ACID
Oceanside Pharmaceuticals	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium phenylacetate and sodium benzoate	68682-001	SODIUM HYDROXIDE
Oceanside Pharmaceuticals	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium phenylacetate and sodium benzoate	68682-001	WATER
MAIA PHARMACEUTICALS	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium phenylacetate and sodium benzoate	70511-102	HYDROCHLORIC ACID

Generic Drugs Containing SODIUM PHENYLACETATE AND SODIUM BENZOATE

Company	Ingredient	NDC	Excipient
Trigen Laboratories LLC	sodium phenylacetate and sodium benzoate	13811-705	HYDROCHLORIC ACID
Trigen Laboratories LLC	sodium phenylacetate and sodium benzoate	13811-705	SODIUM HYDROXIDE
Trigen Laboratories LLC	sodium phenylacetate and sodium benzoate	13811-705	WATER
Mylan Institutional LLC	sodium phenylacetate and sodium benzoate	67457-844	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in SODIUM PHENYLACETATE AND SODIUM BENZOATE?

# Of NDCs	Excipient
13	HYDROCHLORIC ACID
13	SODIUM HYDROXIDE
13	WATER

Sodium Phenylacetate and Sodium Benzoate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Sodium phenylacetate and sodium benzoate injection is an established nitrogen-scavenging therapy for acute hyperammonemia caused by urea-cycle disorders. The commercial opportunity is concentrated in differentiated injectable presentation, pediatric administration, storage and supply reliability, hospital procurement, and formulation-support services rather than new-molecule exclusivity. The reference product, AMMONUL, contains 10% sodium phenylacetate and 10% sodium benzoate and is administered with arginine hydrochloride as part of emergency treatment.[1]

The excipient strategy must preserve chemical stability, maintain intravenous tolerability, support rapid preparation, and avoid increasing the product’s sodium burden. Because the active ingredients are administered at high concentrations, formulation latitude is narrower than for conventional small-molecule injections.

What is sodium phenylacetate and sodium benzoate injection used for?

Sodium phenylacetate and sodium benzoate injection is used as an adjunctive treatment for acute hyperammonemia in patients with urea-cycle disorders. Sodium phenylacetate is metabolized to phenylacetyl-CoA, which conjugates with glutamine to form phenylacetylglutamine. Sodium benzoate is converted to benzoyl-CoA and conjugates with glycine to form hippuric acid. Both metabolites are excreted in urine, providing alternative nitrogen-excretion pathways.[1,2]

The product is administered intravenously and is generally used with hemodialysis when rapid ammonia reduction is required. Treatment is typically combined with caloric support and arginine hydrochloride. The label emphasizes that therapy should be initiated by clinicians experienced in urea-cycle disorders.[1]

What is the active pharmaceutical ingredient profile?

Attribute	Sodium phenylacetate	Sodium benzoate
Therapeutic role	Nitrogen scavenger through glutamine conjugation	Nitrogen scavenger through glycine conjugation
Common injection concentration	100 mg/mL	100 mg/mL
Salt contribution	High sodium load	High sodium load
Administration	Intravenous infusion after dilution	Intravenous infusion after dilution
Primary clinical setting	Acute metabolic decompensation	Acute metabolic decompensation
Key formulation concern	Chemical stability and infusion tolerability	Chemical stability and infusion tolerability

What excipients are used in the reference product?

The reference formulation is a concentrated aqueous injection. The commercial product contains the two active sodium salts in Water for Injection. The formulation does not depend on a conventional preservative system, surfactant, oil phase, or complex delivery excipient.[1]

The label identifies the product as a sterile, nonpyrogenic solution containing 100 mg/mL sodium phenylacetate and 100 mg/mL sodium benzoate. Product pH is controlled during manufacture. The label’s inactive-ingredient profile is limited compared with many injectable products, which reduces opportunities for simple excipient substitution.[1]

Why is the excipient burden commercially important?

A low-excipient formulation creates both an advantage and a constraint:

• It reduces the number of formulation variables that can affect safety.
• It simplifies toxicology and injectable compatibility assessment.
• It limits the ability to differentiate a follow-on product through conventional excipient changes.
• It places greater commercial value on packaging, dilution systems, administration devices, and manufacturing controls.
• It makes pH, osmolality, particulate control, extractables and leachables, and container compatibility central development issues.

The formulation also has a high total sodium content. A 10% concentration of each sodium salt creates a product in which sodium exposure, fluid volume, and infusion rate must be managed clinically. An excipient or buffer strategy that increases sodium concentration would have limited commercial appeal.

What excipient strategies are available for sodium phenylacetate and sodium benzoate?

The strongest formulation strategy is usually a restrained, aqueous, preservative-free system that maintains the reference product’s core composition while improving administration and supply characteristics.

pH control

pH adjustment can support chemical stability and product tolerability. Hydrochloric acid or sodium hydroxide may be used during manufacture to establish the target pH, but these materials are generally process aids or pH adjusters rather than a meaningful commercial differentiation platform.

A new buffer system could create regulatory and technical burdens:

• It may alter degradation pathways.
• It may change compatibility with infusion materials.
• It may affect osmolality.
• It may increase the sodium or chloride burden.
• It may create a new impurity profile.

For a high-concentration emergency injection, a buffer-free or minimally buffered formulation is more commercially defensible unless stability data show a clear benefit.

Chelators and metal-ion control

Trace metals can catalyze degradation in some aqueous products. A chelator such as disodium edetate could theoretically improve stability, but its use would need to be justified by degradation, compatibility, and safety data. Adding a chelator solely to create formulation differentiation would be weak unless it enables a measurable shelf-life, container, or manufacturing benefit.

A chelator can also create new regulatory questions involving elemental impurities, pediatric exposure, and compatibility with infusion equipment. The commercial case is strongest when the excipient solves a documented stability problem.

Tonicity modifiers

Sodium chloride, dextrose, and other tonicity agents could make a formulation more compatible with infusion practice, but sodium chloride is unattractive where sodium exposure is already clinically relevant. Dextrose may create compatibility, microbial, or stability considerations.

Because the product is normally diluted before infusion, an improved ready-to-dilute presentation may have greater value than attempts to make the concentrate isotonic.

Preservatives

A preservative-free single-dose or pharmacy bulk strategy is generally preferable for a high-risk intravenous metabolic emergency product. Preservatives can create toxicity and compatibility issues, especially in neonates, infants, and critically ill patients. A multidose presentation would require a strong commercial rationale and substantial preservative efficacy and container-closure data.

Surfactants and solubilizers

Surfactants are unlikely to be necessary because the active ingredients are water-soluble salts. Their addition could increase particulate, foaming, adsorption, and toxicology risks without solving a clear formulation problem.

What dosage-form opportunities exist?

The most credible opportunities are presentation and workflow improvements rather than a new oral or depot dosage form.

Ready-to-use diluted infusion

A premixed infusion could reduce pharmacy preparation time and dilution errors. Its limitations are:

• Higher shipping weight and volume.
• Greater storage and distribution cost.
• Potentially shorter shelf life.
• More demanding container-closure requirements.
• Increased risk of crystallization or precipitation during storage.
• Need for a suitable infusion bag and administration configuration.

A ready-to-use product could command a premium in pediatric intensive care units, metabolic centers, and emergency departments if it reduces preparation burden without compromising shelf life.

Unit-dose concentrate

A small-volume, single-dose vial remains the most practical presentation for a concentrated product. Commercial differentiation could include:

• Clearer dose-measurement markings.
• Low-sorption container materials.
• Improved withdrawal volume.
• Reduced overfill.
• Pharmacy-ready labeling.
• Barcoded unit-dose packaging.
• Tamper-evident closure systems.

Dual-chamber or co-packaged system

The product is used with arginine hydrochloride and other metabolic-support measures. A co-packaged kit containing sodium phenylacetate/sodium benzoate injection, arginine hydrochloride, dilution supplies, and emergency instructions could improve hospital workflow.

A dual-chamber system that separates concentrate from diluent could reduce stability concerns, but it would require substantial device development, combination-product analysis, and human-factors validation.

Oral or enteral follow-on strategy

Oral sodium phenylbutyrate is an alternative nitrogen-scavenging therapy, but it is not an interchangeable dosage-form substitute for acute intravenous sodium phenylacetate and sodium benzoate. An oral product would face different palatability, absorption, dosing, and chronic-use requirements. It would compete more directly with BUPHENYL and glycerol phenylbutyrate products than with AMMONUL.

What patents protect sodium phenylacetate and sodium benzoate injection?

The active ingredients and the core therapeutic concept are old. The principal commercial protection is therefore unlikely to come from a new-composition patent covering sodium phenylacetate and sodium benzoate as such.

Potentially relevant rights fall into five categories:

IP category	Likely commercial relevance
Active-ingredient composition	Low, because both salts are established pharmaceutical substances
Method of treating urea-cycle disorders	Limited by prior art and claim scope
Specific concentration or ratio	Potentially relevant if a genuinely novel and non-obvious formulation is claimed
Container or delivery system	Moderate opportunity for differentiated products
Manufacturing and impurity control	Potentially useful as trade-secret or process-patent protection

A formulation patent would need to claim more than the known 10%/10% aqueous presentation. Stronger claim themes could include a defined impurity profile, a validated stability advantage, a particular container material, a low-particulate manufacturing process, a premixed infusion composition, or a device that controls dilution and administration.

Patent applicants should avoid relying on broad claims to “a pharmaceutical composition comprising sodium phenylacetate and sodium benzoate.” Such claims would face substantial prior-art exposure. Narrow claims tied to measurable technical effects are more defensible.

What is the Orange Book and FDA regulatory status?

AMMONUL is an FDA-approved prescription injection for acute hyperammonemia associated with urea-cycle disorders. FDA approval is held under an NDA, and the product is regulated as a drug rather than as a biologic.[1,3]

Orange Book analysis should distinguish between:

• The NDA-listed reference product.
• Any active patent or exclusivity listing.
• Authorized generic status.
• An ANDA referencing the NDA.
• A 505(b)(2) application relying partly on published literature or FDA findings.

The product’s age means that new-molecule exclusivity is not commercially relevant. Any current market barrier would more likely involve formulation, manufacturing, supply, regulatory complexity, or limited market size than NCE exclusivity.

Does the product have biosimilar risk?

No. Sodium phenylacetate and sodium benzoate are chemically defined small-molecule salts. Biosimilar pathways under section 351(k) of the Public Health Service Act do not apply. Competitive products would use an ANDA, a 505(b)(2) application, or a full NDA pathway depending on formulation, labeling, and reliance strategy.[3,4]

When does sodium phenylacetate and sodium benzoate lose exclusivity?

The original regulatory and patent exclusivity periods have long expired or are no longer the primary commercial issue. No biologic exclusivity period applies. The main questions for a prospective entrant are whether:

1. The reference product has current FDA-listed patents.
2. The proposed product can qualify for ANDA approval.
3. The formulation differs enough to require a 505(b)(2) application.
4. Any listed patents require a Paragraph IV certification.
5. The applicant can establish injectable equivalence, stability, sterility, and container compatibility.

A current patent-expiration table should be built from the active FDA Orange Book listing and the relevant patent records at the time of filing. The public value of the old active ingredients does not by itself establish freedom to operate for a new container, premix, device, or manufacturing process.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge would be relevant only if an applicable patent is listed for the reference product. A generic applicant would need to certify that the patent is invalid, unenforceable, or will not be infringed. The 30-month stay provisions would depend on the timing and validity of a listed-patent infringement action.[3]

For this product, the more material litigation risks are likely to involve:

• A formulation patent covering a particular concentration or stability profile.
• A container-closure or delivery-device patent.
• A method-of-use patent directed to a specific dosing population.
• Trade-secret claims involving impurity control or manufacturing parameters.
• Trademark disputes involving product naming and packaging.

No broad biosimilar litigation pathway applies. A follow-on applicant should also assess patent rights covering related products, including sodium phenylbutyrate and glycerol phenylbutyrate, if the commercial strategy includes chronic nitrogen-scavenger therapy.

How strong is the patent estate?

The estate around the old active-ingredient combination is likely weak as a composition platform and stronger only where it is tied to a new technical feature.

Estate component	Relative strength	Reason
Sodium phenylacetate alone	Low	Long-established compound
Sodium benzoate alone	Low	Long-established compound
10%/10% aqueous injection	Low to moderate	Known reference formulation limits breadth
Premixed infusion	Moderate	May support new stability and packaging claims
Low-particulate manufacturing	Moderate	Protectable if linked to measurable performance
Container-closure system	Moderate	Device and packaging claims may create differentiation
Pediatric dosing workflow	Low to moderate	Method claims face prior-art and eligibility limits
Trade-secret manufacturing controls	Potentially high	Difficult to replicate without process disclosure

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have a narrower opportunity than in conventional injectable products because the active formulation is simple and highly concentrated. The most attractive commercial targets are:

Injectable-grade water and process systems

Reliable supply of Water for Injection, validated bioburden control, and consistent elemental-impurity performance are essential. A supplier can differentiate through quality systems, supply continuity, and regional manufacturing redundancy.

Low-extractables packaging

Cyclic olefin polymer, glass, elastomer closures, and multilayer infusion bags may support a differentiated product if they reduce adsorption, leachables, particulate burden, or storage constraints. Packaging claims often have greater commercial potential than a new buffer system.

Ready-to-use dilution platforms

Pharmacy compounding systems, transfer devices, and premixed infusion bags can reduce preparation errors. These products may generate revenue through device sales, contract manufacturing, or hospital supply agreements.

Stability-indicating analytical services

Analytical providers can support:

• Phenylacetate and benzoate assay methods.
• Degradation-product characterization.
• Particulate and subvisible-particle testing.
• Container-closure integrity.
• Extractables and leachables.
• In-use and diluted-solution stability.
• Sterility and endotoxin programs.

Contract development and manufacturing

CDMOs with sterile fill-finish capacity, high-concentration aqueous formulation experience, and pediatric injectable packaging are well positioned to support a follow-on product. Manufacturing scale and shortage resilience may be more valuable than a novel excipient.

How does the product compare with other nitrogen scavengers?

Product	Active ingredient	Main use	Administration	Commercial distinction
AMMONUL	Sodium phenylacetate plus sodium benzoate	Acute hyperammonemia	Intravenous	Emergency hospital product
BUPHENYL	Sodium phenylbutyrate	Chronic nitrogen control	Oral	Tablets and granules
RAVICTI	Glycerol phenylbutyrate	Chronic nitrogen control	Oral liquid	Lower dosing volume and palatability positioning
Arginine hydrochloride	Arginine	Adjunct in urea-cycle disorders	Intravenous or oral depending on product	Does not replace nitrogen scavenger
Dialysis	Extracorporeal nitrogen removal	Severe hyperammonemia	Hemodialysis or related modality	Acute rescue and clearance

The intravenous product occupies a specialized emergency segment. Its market is smaller than the chronic oral nitrogen-scavenger market but has higher clinical urgency and greater tolerance for premium pricing when supply is reliable.

What generic launch scenarios exist?

Three launch models are commercially plausible:

1. ANDA-based injectable generic.
   This is the most direct strategy if the product can match the reference formulation, route, concentration, labeling, and presentation.

2. 505(b)(2) differentiated injection.
   This route may fit a premixed infusion, altered container, new dilution system, or presentation with clinical and stability differences from the reference product.

3. Hospital-focused co-packaged product.
   A manufacturer could combine the injection with dilution materials, arginine hydrochloride, and emergency-use labeling. The regulatory classification would depend on the exact configuration.

The largest barriers are likely to be limited annual demand, sterile manufacturing cost, validation of concentrated aqueous stability, hospital contracting, and the need to maintain continuous availability for a rare-disease emergency product.

What is the revenue exposure and market opportunity?

Revenue exposure is concentrated in a small patient population but has high clinical value per treatment episode. Demand is driven by:

• Incidence of urea-cycle disorders.
• Frequency of metabolic crises.
• Number of metabolic referral centers.
• Hospital formulary decisions.
• Product availability during emergencies.
• Treatment duration and use of dialysis.
• Pediatric and neonatal demand.

A supplier should not size the opportunity solely by patient prevalence. The relevant commercial unit is the hospital emergency treatment course, supported by inventory held at specialized centers. Stocking requirements create a recurring demand base even when utilization is infrequent.

The most defensible pricing premium would attach to reduced preparation time, longer shelf life, fewer supply interruptions, lower waste, and validated compatibility with common infusion systems.

What geographic opportunities exist?

The United States is the most structured market because of FDA approval, hospital formulary systems, and established rare-disease treatment centers. Europe, Japan, and other regulated markets may offer opportunities through national approvals, hospital procurement, and local supply partnerships.

Geographic expansion must address:

• Country-specific registration of the active salts.
• Local sterile-manufacturing requirements.
• Pharmacopoeial standards.
• Labeling and dosing conventions.
• Pediatric-use requirements.
• Cold-chain or controlled-storage conditions.
• Reimbursement and hospital tender structures.

A regional manufacturing strategy can reduce supply risk, but multiple sites increase comparability and regulatory-maintenance requirements.

Key Takeaways

• Sodium phenylacetate and sodium benzoate injection is a mature, small-molecule emergency therapy with no biosimilar pathway.
• The reference product uses a simple aqueous formulation containing 10% of each active sodium salt in Water for Injection.
• The principal formulation constraints are sodium burden, high concentration, intravenous tolerability, stability, particulate control, and packaging compatibility.
• Excipient substitution alone is unlikely to create a strong commercial moat.
• The best opportunities are ready-to-use presentations, pharmacy workflow systems, low-extractables packaging, stability improvements, and supply-reliable sterile manufacturing.
• Composition patents covering the old active ingredients are unlikely to provide meaningful protection.
• Stronger IP may be available for validated premixes, container systems, manufacturing controls, impurity profiles, and administration devices.
• Generic entry is more likely to be limited by market size and sterile-manufacturing economics than by original-drug exclusivity.
• A current Orange Book and patent-record review is essential before an ANDA or 505(b)(2) filing.

FAQs

Can sodium phenylacetate and sodium benzoate injection contain preservatives?

A preservative-free presentation is generally more appropriate for emergency intravenous use, especially in pediatric patients. Any preservative strategy would require compatibility, toxicity, preservative-effectiveness, and labeling support.

Can sodium chloride be used as an excipient?

Sodium chloride can affect tonicity and dilution, but it increases the product’s sodium burden. Its use must be justified by a clear stability, administration, or compatibility benefit.

Is a premixed sodium phenylacetate and sodium benzoate infusion commercially attractive?

Yes, if it delivers longer usable shelf life, reduced pharmacy preparation, reliable container compatibility, and lower dosing risk. The economics must overcome higher shipping volume and manufacturing cost.

Are sodium phenylacetate and sodium benzoate interchangeable with sodium phenylbutyrate?

No. Sodium phenylbutyrate is an oral nitrogen scavenger with different pharmacology, dosing, formulation, and clinical use. It is not an automatic substitute for acute intravenous therapy.

What is the strongest IP strategy for a new product?

The strongest strategy is likely a combination of narrow formulation claims, container-closure or delivery-device claims, manufacturing-process protection, and trade-secret control of impurity and stability parameters.

References

1. Ucyclyd Pharma, Inc. (2023). AMMONUL (sodium phenylacetate and sodium benzoate) injection, prescribing information. U.S. Food and Drug Administration labeling database.

2. Häberle, J., Boddaert, N., Burlina, A., Chakrapani, A., Dixon, M., Huemer, M., MacDonald, A., Martín-Hernández, E., Medin, G., Lindner, M., Rubio, V., & Lachmann, R. (2019). Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases, 14, 32.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. FDA, Center for Drug Evaluation and Research.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. International Council for Harmonisation. (2006). ICH Q3C(R8): Impurities: Guideline for residual solvents. ICH.

7. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

8. International Council for Harmonisation. (2020). ICH Q3D(R2): Guideline for elemental impurities. ICH.